The Effects of Two Weeks of Arm Crank Sprint Interval Training in Men with Chronic Spinal Cord Injury

Christopher R Harnish¹, Roy T Sabo², Jonathan A Daniels³ and Deborah Caruso⁴

¹Department of Exercise Science, Shenandoah University, USA
²Department of Biostatistics, Virginia Commonwealth University, USA
³Arizona University School of Medicine, USA
⁴Department of Physical Medicine and Rehabilitation, USA

Abstract

The purpose of this study was to examine the performance and metabolic effects of two weeks of Arm Crank Ergometry (ACE) Sprint Interval Training (SIT) in men with Spinal Cord Injury (SCI). Eight paraplegic males 50.5 ± 9.0 yo, 180.8 ± 6.7 cm tall, 85.1 ± 19.5 kg, and 35.1 ± 5.7% body fat completed three Oral Glucose Tolerance Tests (OGTTs) at baseline, 2 weeks later, prior to SIT, and 48 hrs Post SIT. Six SIT sessions were performed on a Monark 891E ACE. Subjects cranked against 3.5% body mass for 30 sec, completing 4 sprints in session 1, then 5, 5, 6, 6, and 7 sprints in the final session. All data are presented as means ± SD with absolute change responses from baseline ± 95% confidence intervals and changes that failed to cross 0 considered significant. Peak and average power output increased across all subjects; peak power increased 11.9%, while average power increased 9.9%. AUC for neither glucose nor insulin significantly changed and ISI-Cederholm insulin sensitivity also failed to improve; OGTT change was 3.93 (-23.4, 31.3 95% CI). However, post-SIT plasma Non-Esterified Fatty Acid (NEFA) AUC dropped 0.34 (-0.53, -0.16 95% CI) mEq.L⁻¹. In conclusion, two weeks of ACE SIT was effective at reducing NEFA in men with SCI, but did not improve insulin sensitivity or glucose levels. These data indicate that ACE SIT may be an effective adjunct training modality for those with SCI and other non-ambulatory populations.

Keywords

Spinal cord injury, Sprint interval training, Insulin sensitivity, Arm crank ergometry, OGTT

Abbreviations

ACE: Arm Crank Ergometry; BLC: Blood Lactate Concentration; HIT: High-Intensity Interval Training; NEFA: Non-Esterified Fatty Acid; OGTT: Oral Glucose Tolerance Test; SCI: Spinal Cord Injury; SIT: Sprint Interval Training; WIN: Wingate Training; WR: Work-to-Rest ratio

More than 6 million (~2%) Americans are living with a spinal cord injury or disorder [1]. Numerous studies have shown that up to half of persons with Spinal Cord Injury (SCI) are obese, with nearly 70% of persons with SCI exhibiting two or more components of Metabolic Syndrome [2-5], with poor glucose and insulin regulation being most common [6]. Due to the close relationship between metabolic syndrome and both obesity and blood sugar management, mitigating either or both of these conditions is a priority for many populations, including SCI.

Exercise is effective in reducing body fat [7] and improving many of the components of metabolic syndrome, like insulin resistance [8-10]. Exercise intensity, however, has been postulated as the critical component between improved mitochondrial function and Glucose Transporter (GLUT) 4 expression. Earnest [9] hypothesized that High-Intensity Interval (HIT), using efforts at > 80% VO₂Peak, may offer a more powerful stimulus improving insulin sensitivity than moderate aerobic exercise, relating specifically to the aerobic metabolic processes (e.g., aerobic glycolysis, beta oxidation, and mitochondrial biogenesis). Similarly, Sprint Interval Training (SIT), which uses repeated “supramaximal” sprints above VO₂
Upper extremity training is effective at improving central and peripheral fitness markers, and may transfer to lower extremity fitness [7,16]. Although training the upper extremities does improve force production and endurance of the muscles trained, intensity appears to be a critical factor in upper extremity fitness and transfer to lower extremity fitness [7]. Little is known, however, on the impact of specific Arm Crank Ergo Meter (ACE) interventions, including the adaptation of many HIT protocols, as well as SIT.

The purpose of this exploratory study was to examine the efficacy of six sessions of ACE SIT on sprint performance and metabolic factors, including insulin sensitivity and plasma NEFAs. We hypothesized that ACE SIT would improve sprint power output, as well improve peripheral insulin sensitivity (ISI-Cederholm), and reduce plasma NEFAs from pre-regimen levels in men with SCI.

### Methods

#### Experimental approach to the problem

In order to closely compare the effect of short-term SIT on persons with SCI, the experimental protocol (Figure 1) was similar to previous SIT studies [12-14], utilizing the same work to rest ratio, which amounted to sessions lasting about 20 min, with 3 sessions conducted over 2 weeks. Due to difficulty in recruiting and transporting persons with SCI, we utilized a 2-week control period allowing each subject to act as their own control. During this period, two Oral Glucose Tolerance Tests (OGTT 1 and 2) were compared, while lifestyle and activity remained unchanged; a dietary recall was completed for the 24-hr period prior to each OGTT. DXA body composition analysis was completed during the first test session. To minimize learning effects during training, subjects were familiarized with ACE Wingate training no less than 6 days prior to OGTT 2 to prevent any possible effect on blood test. Once completed, each participant began their sprint training within 36-hours after the second pre-training OGTT2.

A total of six sprint training sessions took place over a period of 2 weeks. A final post-post-training OGTT3 was performed between 48 and 60 hrs of the final training session; this time period matched previously published work [12]. The Area Under the Curve (AUC) was calculated for glucose, insulin, and NEFA’s for pre and post blood testing. Utilizing this protocol, we surmised that baseline and pre-training blood variables would not change, while those same variables would change as shown in other studies [12-14] after six sessions of SIT. Enrollment and testing began in June 2010 and were concluded approximately 18 mo later.

#### Subjects

All experimental protocols were reviewed and approved by the Hunter Holmes McGuire VAMC institutional review board and comply with the Declaration of Helsinki. All participants were actively recruited through word of mouth, flyers and call lists, with individuals being both veterans visiting the Hunter Holmes McGuire Veterans Administration Medical Center (VAMC) and individuals living in the greater Richmond, Virginia (USA) Community. Subjects were enrolled in the study following completion of the McGuire IRB approved informed consent document. A detailed medical history and American College of Sports Medicine (ACSM) risk factor assessment was performed for all participants and each subject was reviewed by an SCI board-certified physician. Only individuals considered paraplegics (i.e., T1-L2) AIS (American Spinal Injury Association Classification)-A through D for 3 months or longer were considered for the study. Individuals classified as High Risk based on established ACSM criteria, persons with known orthopedic limitations, diabetes mellitus (fasting glucose > 126 or HgbA1c > 7.0), hypothyroidism, renal disease, uncontrolled autonomic dysreflexia, recent (within 3 months) deep vein thrombosis, or pressure ulcers > Stage II were excluded from participation. A total of 12 sedentary men with T1-T10 SCI initiated the study,
with eight completing the entire protocol; subject withdrawal was due to lack of transportation to the laboratory, with three withdrawing prior to beginning SIT, and one after their second sprint session.

**Procedures**

Subjects were instructed to maintain their usual diet throughout the study and to consume similar meals the day before each OGTT; a standard 24-hr dietary recall form for the day prior to the OGTT, with subsequent forms completed preceding each OGTT. Subjects were also instructed to consume 8-16 oz of water prior to their arrival for testing. During the pre-training control period and after the first OGTT, each subject completed one VO2 Peak testing and this was used to assess physical readiness and determine maximum 2 min power. Testing was performed using a Lode upper extremity ergo meter (Electro-Med Corporation, Flint, MI). Subjects performed the test in their own stabilized wheelchair with appropriate seating, trunk support, leg wraps, abdominal binder and protective hand mitts provided. Each subject cranked at 70 RPM against no resistance for 3 min before work rate was increased by 15 W every 3 min until volitional exhaustion was reached. VO2 and HR were measured continuously using a Cosmed K4b2 (Cosmed USA, Inc. Chicago, IL) and Polar RS 400 HR monitor (Polar Electro Inc., Lake Success, NY), respectively, and stored for later analysis. Subjects were familiarized with the training protocol no less than 5 days prior to training to mitigate any influence on the Pre OGTT. Each subject repeated this test after their final OGTT.

Sprint training was performed using a mechanically braked Monark 891E arm crank ergo meter (Fitness Superstore, Inc., Concord, CA), while sitting in their own stabilized wheelchair with appropriate seating, trunk support, leg wraps, abdominal binder and protective hand mitts provided. Following 10 min of unloaded warm-up at 30-50 rpm, each subject cranked as fast as possible for 30 sec against a resistance equivalent to 0.035 kg/kg (3.5%) body weight a resistance shown to be suitable for thoracic level persons with SCI in the pilot phase of the study [16]. Subjects cranked while being provided with vigorous verbal encouragement throughout each sprint. Peak and mean power (W) and total work (kJ) were recorded using the software provided with the ergo meter. Each sprint was followed by ~5 min of rest or slow reverses pedaling. The initial training session included four sprints progressing to five sprints in sessions 2 and 3, six sprints in sessions 4 and 5, and finally seven sprints in the final session. Sessions were separated by at least 48 hrs, but no more than 72 hrs (i.e., one weekend). During sessions 1 and 6, 5 μl blood lactate samples were taken from the subjects earlobe using a small plastic lancet and immediately analyzed using a Lactate Scout Analyzer (Sports Resource Group, Hawthorne, NY). Samples were taken prior to training, after sprint 1, 4 and 7 (during session 6), and 1 and 3 min post exercise. Each training session lasted approximately 30 min. Due to the increase in the number of sprints performed during training; the relative improvement in sprint work capacity was compared using the total kJ expenditure.

All OGTT’s were performed between 0800 and 1000 hours, and each subject’s tests were conducted at the same time (±5 min) of the first test. Subjects refrained from performing any strenuous physical activity for a period of 72 hrs prior to baseline and Pre OGTT, and arrived at the laboratory following at least a 12 hr overnight fast. Venous blood samples (~10 ml) were collected by venipuncture before ingestion, and at 60, 90 and 120 min after ingestion of 75 g glucose (NOW Foods, Bloomingdale, IL) dissolved in 100 ml of water. Plasma was separated by centrifugation (15 min at 7000 rpm) and stored at -20 °C until analysis of glucose, insulin, and NEFA concentrations. All samples were measure in duplicate. Plasma glucose concentrations were measured using an auto-analyzer glucose oxidase method, while plasma insulin concentrations were determined by ELISA (R & D Systems, Inc, Minneapolis, MN). Plasma NEFA concentrations were determined by a colorimetric assay (Wako Chemicals, Germany) using a modified protocol. Briefly 3.75 μl of plasma samples and standards of known concentration were pipetted into a 96-well plate 75 μl of color reagent A were added to each well and incubated at 37 °C for 10 min. 150 μl of colour reagent B were added and incubated for a further 10 min at 37 °C. The plate was then removed from the incubator and allowed to cool to room temperature prior to the absorbance being read at 550 nm. In order to assess normal intra-individual variation in response to an OGTT over a period of several weeks as used in the present study, all subjects performed the initial OGTT prior to any testing in week 0 and compared to the Pre training test at week 2. Coefficients of Variation (CV) for glucose, insulin, and NEFA were 5.6%, 6.1%, and 6.6%, respectively.

**Statistical analyses**

Data were analyzed using Jump 13.0 software (SAS Institute Inc., Cary, NC). All data are presented as means ± SD. The Area Under the Curve (AUC) was calculated using the trapezoidal rule and peripheral Insulin Sensitivity (S) was estimated using ISI-Cederholm.

\[
\text{Cederholm SI} = \frac{75000 + (G_0 - G_{2h2}) \times 1.15 \times 180 + 0.19 \times \frac{BW}{G_{Gmean}} \times \log(\text{Gmean})}{1000}
\]

\[
BW = \text{body weight}, \ G_0 \text{ and } G_{2h2} \text{ are plasma glucose concentration at 0 and 120 min (mmol.l}^{-1}\text{)}, \text{ and } I_{\text{mean}} \text{ and } G_{\text{Gmean}} \text{ are the mean insulin (Mu.l}^{-1}\text{)} \text{ and glucose (mmol.l}^{-1}\text{)} \text{ concentrations during the OGTT.}
\]

Dependent variables, like insulin sensitivity, glucose, insulin, and NEFA AUC, as well as sprint performance markers are reported as absolute values and changes from baseline. Data were analyzed using absolute change responses from baseline ± 95% confidence inter-
The purpose of this study was to evaluate the efficacy of arm crank SIT for paraplegic men. Based on the research available for leg sprinting [12–14] and upper extremity training [7,17] at the time of the study, we speculated that ACE SIT could improve sprint performance and metabolic factors in men with chronic SCI. Following 2-week of arm crank SIT, there were significant improvements in performance measures including both sprint and aerobic measures. While, SIT failed to produce significant improvement in glucose tolerance or insulin sensitivity, we did see a significant reduction in NEFA curves. These findings suggest that SIT can have substantial impact on performance indices but not carbohydrate metabolism in men with SCI.

The untrained male participants in this study showed a high training capacity with an improvement in sprint power output and average work of about 10%, and an improvement in aerobic power output of nearly 20%. Contemporary performance research typically considers a 1% improvement as the least meaningful improvement for events lasting 30 sec or less [18], indicating that our findings represent almost certain improvements in performance that were consistent across all subjects. While the increased in aerobic power are most likely tied to improved motor unit recruitment [11], the greater overall work capacity would improve overall upper extremity power, an important fitness component for wheelchair propulsion and activities of daily living [19–22]. For example, loss of upper extremity strength and power significantly increases one’s risk for premature mortality [21], and strength and power have a profound influence on one’s ability to perform activities of daily living and wheelchair propulsion [19,22]. SIT can also provide enhanced power for wheelchair propulsion, reducing physical strain and improving one’s ability to perform activities of daily living; all essential aspects to long-term health.

Table 1: Summary of physiological and performance changes before and after six Sprint Interval Training (SIT) sessions. Note, VO$_2$ Peak testing was conducted prior to and after SIT. SIT power and work data were taken from the first four sprints of each session. *95% CI changes that failed to cross 0 (i.e., 0 change) were considered significant with a significant increase above initial values.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Change Mean (95% CI)</th>
<th>% Change Mean (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VO$_2$ Peak (L min$^{-1}$)</td>
<td>1.02 (0.04, 2.10)</td>
<td>7.6 (1.5, 11.1)$^*$</td>
</tr>
<tr>
<td>VO$_2$ Peak Power (W)</td>
<td>13.1 (5.1, 21.2)$^*$</td>
<td>17.9 (3.7, 30.4)$^*$</td>
</tr>
<tr>
<td>Peak Power (W)</td>
<td>34.1 (13.3, 54.8)$^*$</td>
<td>11.9 (4.3, 19.5)$^*$</td>
</tr>
<tr>
<td>Mean Power (W)</td>
<td>23.7 (7.3, 40.1)$^*$</td>
<td>9.9 (2.2, 17.7)$^*$</td>
</tr>
<tr>
<td>% VO$_2$ Peak Power</td>
<td>-13.8 (-29.1, 1.5)</td>
<td>--</td>
</tr>
<tr>
<td>Work (kJ)</td>
<td>0.69 (0.22, 1.15)$^*$</td>
<td>12.0 (4.6, 19.4)$^*$</td>
</tr>
<tr>
<td>BLC (mM)</td>
<td>0.8 (-1.9, 0.2)</td>
<td>--</td>
</tr>
</tbody>
</table>

Table 2: Summary of Pre- and Post-Test Areas under Curves for glucose, insulin, and NEFA, and ISI-Cederholm changes before and after six Sprint Interval Training (SIT) sessions. *95% CI changes that failed to cross 0 (i.e., 0 change) were considered significant with a significant increase above initial values.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Change Mean (95% CI)</th>
<th>% Change Mean (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg dL$^{-1}$)</td>
<td>76.2 (18.1)</td>
<td>-0.4 (-11.8, 11.0)</td>
</tr>
<tr>
<td>Insulin (mU·l$^{-1}$)</td>
<td>139.0 (52.9)</td>
<td>-29.5 (-91.3, 32.4)</td>
</tr>
<tr>
<td>NEFA (mEq·L$^{-1}$)</td>
<td>1.01 (0.46)</td>
<td>-0.34 (-0.53, -0.16)$^*$</td>
</tr>
<tr>
<td>ISI-Cederholm</td>
<td>175.2 (46.3)</td>
<td>3.93 (-23.4, 31.3)</td>
</tr>
</tbody>
</table>
It is well documented that persons with SCI suffer a multitude of metabolic disruptions [2-6,23], therefore improvements in metabolic markers are an important outcome for exercise. Unfortunately, SIT failed to influence carbohydrate metabolism or insulin sensitivity. Our data indicate that neither resting glucose, insulin, nor their AUC’s were reduced following SIT; likewise, peripheral insulin sensitivity also failed to show improvement. While earlier research indicated that SIT could improve insulin sensitivity, acute SIT using either short or long rest periods [24] failed to improve insulin sensitivity among healthy untrained individuals. In fact, 2017 meta-analysis [25] suggests that neither short nor long-term SIT improves blood glucose-related control mechanisms. Add to this the high day-to-day variability (23% CV) in glucose and insulin response was too great to overcome with upper extremity exercise alone. Our subjects reflected typical body fat levels (> 30%) seen after SCI, and ACE has been shown to produce lower work outputs [4]. Moreover, other researchers have encountered similar problems using the OGGT (Personal Communication, T. Ryan 2012), and even the Intravenous Glucose Tolerance Test (IVGTT) data (unpublished) from our lab suggest that it may not be an ideal test to assess metabolic improvements for persons with SCI. In contrast, [12] reported a CV in glucose AUC of less than 5%. These variations could not be accounted for by diet, which was monitored and showed minimal variations 24-hr prior to each OGGT.

In contrast to glucose and insulin, we did see significant reduction in plasma NEFA AUC indicating that some blood lipids may be influenced by SIT, and that NEFA’s may be a useful metabolic training marker in persons with SCI [17]. Further, our 2-hour trends in NEFA levels relate closely to those published by Babraj, et al. [12] following lower extremity sprints (Figure 2). Elevated plasma NEFA levels have been shown to directly and indirectly impair insulin sensitivity [26,27]; persons with SCI show elevated NEFA levels [3,6], making reductions an important outcome with training. A reduction in NEFA in the blood could indirectly improve insulin sensitivity [27]. Moreover, long-term training utilizing SIT and resistance training could significantly impact factors other than just glucose metabolism. For example, [17] demonstrated that three months of combined aerobic and resistance circuit training significantly improves both cardiovascular fitness and blood lipid profiles in men with SCI, while Jacobs [20] demonstrated impressive cardiovascular and power enhancements from heavy resistance training alone.

Application of interval training for persons with SCI remains lacking. Our data suggest that high-intensity interval and sprint interval training can be applied using established training principles and may afford an additional modality for training and overall improvement in quality of life, regardless of metabolic improvement. For example, we recently published a case report [28] of one of the individuals completing this SIT study, a T1 AIS-A male, took part in a 12-wk mixed interval ACE training program consisting of only three 30 min training sessions each week. Over the course of the 3-month training period the individual saw a 50% increase in VO$_{2}$ Peak and a 56% improvement in 30 min arm crank time trial performance. Clearly, more work is needed in this

![Figure 2: Illustrative comparison of NEFA values Pre and Post training for our SCI group (Triangle) and means reported by Babraj, et al. (Square)*. Both study groups showed a significant in AUC. *Adapted with permission.](image-url)
area to optimize training programs for persons with SCI care should be taken when implementing SIT with each individual.

This study demonstrates that just 2-wk of SIT can have a substantial impact on upper extremity power in men with SCI. Nonetheless, we recognize that the major limitation in this study is the relatively small sample size of diverse individuals with SCI. A larger study, perhaps with greater dietary controls, including prepared meals, may yield greater metabolic improvements. And while the latest review of research suggests that SIT may offer limited value for managing blood sugar, physical performance improvements are in many ways equally important, as they improve individual independence and work capacity, making further participation in activity more likely. More research is needed to elucidate the effects of longer duration interval programs for those with SCI.

Acknowledgements

All research was made possible with the funding support of VHA RR&D Merit Grants B3918R and B6757R247, and Virginia Commonwealth University’s Center for Clinical and Translational research grant #UL1TR000058, NCATS (National Center for Advancing Translational Sciences), NIH. We wish to thank Allison Keeley for her help in collecting and analyzing the data, and greatly appreciate the effort of all our subjects during the strenuous training protocol.

Conflict of Interest Statement

We report no known conflicts of interest.

Ethical Statement

All experimental protocols were reviewed and approved by the Hunter Holmes McGuire VAMC institutional review board and comply with the Declaration of Helsinki.

Funding Sources

All research was made possible with the funding support of VHA RR&D Merit Grants B3918R and B6757R247, and Virginia Commonwealth University’s Center for Clinical and Translational research grant #UL1TR000058, NCATS (National Center for Advancing Translational Sciences), NIH.

References


